Jean-Guy Bienvenu

An Analysis of Pharmaceutical Experience with Decades of Rat Carcinogenicity Testing

Frank D. Sistare, Daniel Morton, Carl L. Alden et al. · Toxicologic Pathology · 2011 · 152 citations · Full text

Chemoprevention Strategy, Pathology, Toxicology Testing +17

Recombinant Soluble P-Selectin Glycoprotein Ligand-1-Ig Reduces Restenosis Through Inhibition of Platelet-Neutrophil Adhesion After Double Angioplasty in Swine

Jean-Guy Bienvenu, Jean‐François Tanguay, Jean‐François Théorêt et al. · Circulation · 2001 · 75 citations

P-Selectin Antagonism with Recombinant P-Selectin Glycoprotein Ligand-1 (rPSGL-Ig) Inhibits Circulating Activated Platelet Binding to Neutrophils Induced by Damaged Arterial Surfaces

Jean‐François Théorêt, Jean-Guy Bienvenu, Anjali Kumar et al. · Journal of Pharmacology and Experimental Therapeutics · 2001 · 54 citations

Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture

James R. Turk, Aimée M. Deaton, Jun Yin et al. · Regulatory Toxicology and Pharmacology · 2020 · 46 citations · Full text

Sclerostin, Cardiovascular Pharmacology, Pharmacotherapy +18

Mechanisms of action of the tumor necrosis factor and lymphotoxin ligand-receptor system.

Krzysztof Warzocha, Jean-Guy Bienvenu, Bertrand Coiffier et al. · PubMed · 1995 · 43 citations

Inflammation, Lymphotoxin Ligand-receptor System, Tumor Necrosis Factor +14